[go: up one dir, main page]

MX9203504A - Complejo agente: lipido activo de alta proporcion. - Google Patents

Complejo agente: lipido activo de alta proporcion.

Info

Publication number
MX9203504A
MX9203504A MX9203504A MX9203504A MX9203504A MX 9203504 A MX9203504 A MX 9203504A MX 9203504 A MX9203504 A MX 9203504A MX 9203504 A MX9203504 A MX 9203504A MX 9203504 A MX9203504 A MX 9203504A
Authority
MX
Mexico
Prior art keywords
high proportion
agent complex
active lipid
proportion active
lipid
Prior art date
Application number
MX9203504A
Other languages
English (en)
Inventor
Sharma R Minchey
Cristine E Swenson
Andrew S Janoff
Lawrence Boni
Kathy A Stewart
Walter Perkins
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Publication of MX9203504A publication Critical patent/MX9203504A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461Dispersions, colloids, emulsions or suspensions
    • A61K49/0466Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX9203504A 1988-04-20 1992-06-26 Complejo agente: lipido activo de alta proporcion. MX9203504A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18379388A 1988-04-20 1988-04-20
US19691388A 1988-05-20 1988-05-20
US35502889A 1989-05-22 1989-05-22

Publications (1)

Publication Number Publication Date
MX9203504A true MX9203504A (es) 1992-07-01

Family

ID=27391747

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203504A MX9203504A (es) 1988-04-20 1992-06-26 Complejo agente: lipido activo de alta proporcion.

Country Status (2)

Country Link
US (1) US5415867A (es)
MX (1) MX9203504A (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406713B1 (en) * 1987-03-05 2002-06-18 The Liposome Company, Inc. Methods of preparing low-toxicity drug-lipid complexes
IL115099A (en) * 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
NZ504188A (en) * 1997-11-14 2001-10-26 Skyepharma Inc Emulsification process for preparing multivesicular liposomes
US6726650B2 (en) * 1997-12-04 2004-04-27 Bracco Research S.A. Automatic liquid injection system and method
ID28166A (id) * 1998-05-20 2001-05-10 Liposome Co Inc Formulasi partikulat baru
US6613352B2 (en) 1999-04-13 2003-09-02 Universite De Montreal Low-rigidity liposomal formulation
US6676930B2 (en) 1999-11-28 2004-01-13 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
US6861060B1 (en) 2000-04-21 2005-03-01 Elena Luriya Personal care formulations
HUP0302352A3 (en) * 2000-11-09 2007-03-28 Neopharm Sn-38 lipid complexes and methods of use
WO2003030864A1 (en) * 2001-05-29 2003-04-17 Neopharm, Inc. Liposomal formulation of irinotecan
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
CA2471960A1 (en) * 2002-01-09 2003-07-24 Elan Pharmaceuticals, Inc. Efficient liposomal encapsulation
US6931748B2 (en) * 2002-04-05 2005-08-23 Varco I/P, Inc. Riser and tubular inspection systems
CA2752143C (en) * 2002-05-15 2014-09-23 Sutter West Bay Hospitals Delivery of nucleic acid-like compounds
AU2003296897A1 (en) * 2002-08-20 2004-05-04 Neopharm, Inc. Pharmaceutical formulations of camptothecine derivatives
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
CA2499573A1 (en) * 2002-09-24 2004-04-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
HUE029994T2 (en) 2005-12-08 2017-04-28 Insmed Inc Lipid-based compositions of antiinfectives for treating pulmonary infections
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US20090105126A1 (en) * 2007-10-23 2009-04-23 Xingong Li Methods of Treating Pulmonary Disorders using Liposomal Vancomycin Formulations
US20100166739A1 (en) * 2008-12-30 2010-07-01 Lipella Paharmaceuticals Inc. Methods and Compositions for Diagnosing Urological Disorders
RU2675859C2 (ru) 2012-11-29 2018-12-25 Инсмед Инкорпорейтед Стабилизированные составы ванкомицина
AU2015258947B2 (en) 2014-05-15 2020-04-09 Insmed Incorporated Methods for treating pulmonary non-tuberculous mycobacterial infections
EP3773505A4 (en) 2018-03-30 2021-12-22 Insmed Incorporated PROCESS FOR THE CONTINUOUS MANUFACTURING OF LIPOSOMAL MEDICINAL PRODUCTS
CA3098573A1 (en) 2018-05-02 2019-11-07 Insmed Incorporated Methods for the manufacture of liposomal drug formulations
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12285419B2 (en) 2021-10-14 2025-04-29 Pacira Pharmaceuticals, Inc. Bupivacaine multivesicular liposome formulations and uses thereof
US12246092B1 (en) 2024-05-20 2025-03-11 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1514389A (en) * 1975-12-08 1978-06-14 Abbott Lab Glycerides with antibacterial properties
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
DE3068743D1 (en) * 1980-01-16 1984-08-30 Weder Hans G Process and dialysis-installation for the preparation of bilayer-vesicles and their use
IL64397A0 (en) * 1981-01-07 1982-02-28 Weder Hans G Process for the preparation of liposomal medicaments
US4522803A (en) * 1983-02-04 1985-06-11 The Liposome Company, Inc. Stable plurilamellar vesicles, their preparation and use
US4588578A (en) * 1983-08-08 1986-05-13 The Liposome Company, Inc. Lipid vesicles prepared in a monophase
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
CA1237671A (en) * 1983-08-01 1988-06-07 Michael W. Fountain Enhancement of pharmaceutical activity
US4708861A (en) * 1984-02-15 1987-11-24 The Liposome Company, Inc. Liposome-gel compositions
DE3585967D1 (de) * 1984-03-08 1992-06-11 Phares Pharma Holland Liposombildende zusammensetzung.
GB2156345B (en) * 1984-03-30 1987-07-08 Squibb & Sons Inc Alkylamine salts of 3,5-diacetylamino-2,4,6-triiodobenzoic acid as x-ray contrast agents
JPS6150912A (ja) * 1984-08-16 1986-03-13 Shionogi & Co Ltd リポソ−ム製剤の製造法
US4567034A (en) * 1984-09-07 1986-01-28 E. R. Squibb & Sons, Inc. Esters of diatrizoic acid as X-ray contrast agents
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
CH672733A5 (es) * 1987-05-22 1989-12-29 Bracco Ind Chimica Spa

Also Published As

Publication number Publication date
US5415867A (en) 1995-05-16

Similar Documents

Publication Publication Date Title
MX9203504A (es) Complejo agente: lipido activo de alta proporcion.
IT8720894A0 (it) Agente antistatico.
DE69014498D1 (de) Hyposensibilisierende wirksame Substanz.
ES2018451A4 (es) Material microencapsulado agricolamente activo
FI904444A0 (fi) Aktiva limkompositioner.
DE3869446D1 (de) Desodorierungsmittel.
DE68910106D1 (de) Vaginalschwamm.
FI902876A0 (fi) Tvaettmedelspartiklar innehaollande en aktiv komponent och despergerbara i kallt vatten.
DE68914495D1 (de) Antihypercholesterolemisches Mittel.
DE69014166D1 (de) Aktive Matrix.
DE69003121D1 (de) Filmbildendes Mittel.
FI921416L (fi) Cylinderformad uppvaermnings-/ syresaettningsanordning foer blod.
DE68915269D1 (de) Polyvalentes entzündungshemmendes mittel.
NO890504D0 (no) Vandig, flytende blekepreparat.
NO870533D0 (no) Terapeutisk aktive 3-alkoksy-2-aminopropylaminer.
AT375957B (de) Oberflaechenaktives mittel
FI903613A7 (fi) Luovutussysteemi aktiiviaineita varten
DE68910366D1 (de) Schaummittel.
NO902774D0 (no) Aktiv pluggbar funksjonsenhet.
MX9200532A (es) Agente farmaceuticos.
DE3881198D1 (de) Antiviraler wirkstoff.
NO894862D0 (no) Petroleumsstroem-mikroboelge-vannandelsmonitor.
NO910022D0 (no) Fungiside virkestoffkombinasjoner.
DE3868474D1 (de) Insektizides mittel.
ATE100094T1 (de) Imidazolantiarrythmische mittel.